AmeriPath to Report Financial Results for Second Quarter and Six Months Ended June 30, 2001 - Tuesday, July 31, 2001, Before Market -.Business Editors RIVIERA BEACH, Fla.--(BUSINESS WIRE)--July 24, 2001 AmeriPath, Inc. (Nasdaq:PATH), the largest physician and laboratory company focused on providing anatomic pathology, cancer diagnostic, genomics, and healthcare information services See Information Systems. , today announced plans to release its financial results for the second quarter and six months ended June 30, 2001 on Tuesday, July 31, 2001, before the market opens. The Company will broadcast its second quarter financial results conference call on Tuesday, July 31, 2001, at 10:00 a.m. Eastern Time over the Internet. All stockholders and investors are encouraged to participate. This event is available by visiting the Investor Relations Investor relations The process by which the corporation communicates with its investors. page on the Company's website located at http://www.ameripath.com, or through CCBN's Street Events website, located at http://www.streetevents.com. Listeners should go to the website and enter the Individual Investor Center at least 15 minutes before the call to register, download, and install any necessary audio software. For those unable to attend the live webcast, a replay will be available for the next 60 days. There is no charge to access the event. A replay of the call will also be available by telephone beginning at 12:00 p.m., July 31 to 12:00 p.m., August 2. The dial-in number is 800/633-8284, ID No. 19362392. The call will by hosted by James C. New, Chairman and Chief Executive Officer, and Gregory A. Marsh, Vice President and Chief Financial Officer. AmeriPath is a leading national provider of cancer diagnostics, genomics, and related information services. The Company's extensive diagnostics infrastructure includes 425 pathologists and doctorate-level scientists, 42 independent pathology laboratories, the Center for Advanced Diagnostics (CAD), and Dermpath Diagnostics. CAD provides specialized diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease and information services including Fluorescence In-Situ Hybridization hybridization /hy·brid·iza·tion/ (hi?brid-i-za´shun) 1. crossbreeding; the act or process of producing hybrids. 2. molecular hybridization 3. (FISH), Flow Cytometry, DNA Analysis, Polymerase Chain Reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) ), Molecular Genetics, Cytogenetics cytogenetics /cy·to·ge·net·ics/ (-je-net´iks) the branch of genetics devoted to cellular constituents concerned in heredity, i.e. chromosomes. , and HPV HPV human papillomavirus. HPV abbr. human papilloma virus Human papilloma virus (HPV) Typing. Dermpath Diagnostics, with 60 board-certified dermatopathologists, is the country's leading provider of dermatopathology services in the growing skin diagnostic testing market. Additionally, AmeriPath provides clinical trial and research and development support to firms involved in developing new cancer and genomic diagnostic and therapeutics. Editor's Note: This release is also available at http://www.ameripath.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion